secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001641489-23-000051
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q2 2023 net loss $5.6M ($0.07/shr); R&D spend up on cadisegliatin; Nasdaq extension granted
--------------------------------------------------------------------------------

- Net loss of $5.6M ($0.07 per share) vs $3.2M ($0.04) in Q2 2022; no quarterly revenue.
- R&D expenses $4.7M, up 113% from $2.2M, driven by cadisegliatin drug product costs.
- Cash $12.6M at June 30, 2023, up modestly from $12.1M at Dec 31, 2022.
- Nasdaq extended deadline to regain $1 bid compliance to Dec 18, 2023 (granted July 17).
- Phase 3 study for cadisegliatin (TTP399) expected to initiate by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/0001641489-23-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/vtvt-20230811.htm
  HTML page:      https://secwatch.observer/filing/0001641489-23-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer